| ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients D Chu, C Paoletti, C Gersch, DA VanDenBerg, DJ Zabransky, ... Clinical cancer research 22 (4), 993-999, 2016 | 188 | 2016 |
| Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms C Paoletti, AK Cani, JM Larios, DH Hovelson, K Aung, EP Darga, ... Cancer research 78 (4), 1110-1122, 2018 | 114 | 2018 |
| Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients … DL Hertz, MV Caram, KM Kidwell, JN Thibert, C Gersch, NJ Seewald, ... Pharmacogenomics 17 (3), 231-240, 2016 | 74 | 2016 |
| Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer NL Henry, TC Skaar, J Dantzer, L Li, K Kidwell, C Gersch, AT Nguyen, ... Breast cancer research and treatment 138, 807-816, 2013 | 63 | 2013 |
| Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer TL Gonzalez, M Hancock, S Sun, CL Gersch, JM Larios, W David, J Hu, ... Breast Cancer Research and Treatment 180, 611-622, 2020 | 60 | 2020 |
| Predictors of recovery of ovarian function during aromatase inhibitor therapy NL Henry, R Xia, M Banerjee, C Gersch, D McConnell, D Giacherio, ... Annals of oncology 24 (8), 2011-2016, 2013 | 44 | 2013 |
| PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer EP Darga, EM Dolce, F Fang, KM Kidwell, CL Gersch, S Kregel, ... PLoS One 16 (11), e0260124, 2021 | 43 | 2021 |
| Short-term CDK4/6 inhibition radiosensitizes estrogen receptor–positive breast cancers AM Pesch, NH Hirsh, BC Chandler, AR Michmerhuizen, CL Ritter, ... Clinical Cancer Research 26 (24), 6568-6580, 2020 | 38 | 2020 |
| Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses DL Hertz, KM Kidwell, JN Thibert, C Gersch, MM Regan, TC Skaar, ... Molecular oncology 9 (9), 1868-1876, 2015 | 36 | 2015 |
| Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA JM Rae, MM Regan, JN Thibert, C Gersch, D Thomas, B Leyland-Jones, ... Journal of the National Cancer Institute 105 (17), 1332-1334, 2013 | 34 | 2013 |
| Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer DL Hertz, KM Kidwell, NJ Seewald, CL Gersch, Z Desta, DA Flockhart, ... The pharmacogenomics journal 17 (6), 521-527, 2017 | 28 | 2017 |
| Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines TL Gonzalez, RK Moos, CL Gersch, MD Johnson, RJ Richardson, ... Toxicological Sciences 164 (1), 50-59, 2018 | 22 | 2018 |
| Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity Z Chen, B Hu, RK Rej, D Wu, RK Acharyya, M Wang, T Xu, J Lu, ... Journal of Medicinal Chemistry 66 (17), 12559-12585, 2023 | 21 | 2023 |
| Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy LA Marcath, KM Kidwell, K Vangipuram, CL Gersch, JM Rae, ML Burness, ... British Journal of Clinical Pharmacology 86 (5), 880-890, 2020 | 19 | 2020 |
| Further evidence that OPG rs2073618 is associated with increased risk of musculoskeletal symptoms in patients receiving aromatase inhibitors for early breast cancer DL Hertz, KL Smith, Y Zong, CL Gersch, AM Pesch, J Lehman, ... Frontiers in Genetics 12, 662734, 2021 | 13 | 2021 |
| Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer C Van Poznak, EL Reynolds, CL Estilo, M Hu, BP Schneider, DL Hertz, ... Oral diseases 28 (1), 193-201, 2022 | 12 | 2022 |
| Genetic variation in Charcot–Marie–Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy Y Chen, F Fang, KM Kidwell, K Vangipuram, LA Marcath, CL Gersch, ... Pharmacogenomics 21 (12), 841-851, 2020 | 10 | 2020 |
| Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant AL Pasternak, KM Kidwell, JM Dempsey, CL Gersch, A Pesch, Y Sun, ... Pharmacogenomics 20 (6), 421-432, 2019 | 10 | 2019 |
| Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients DL Hertz, KA Speth, KM Kidwell, CL Gersch, Z Desta, AM Storniolo, ... Breast cancer research and treatment 165, 659-668, 2017 | 9 | 2017 |
| Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy AL Pasternak, LA Marcath, Y Li, V Nguyen, CL Gersch, JM Rae, D Frame, ... Transplantation and Cellular Therapy 28 (1), 19. e1-19. e7, 2022 | 8 | 2022 |
